BioSpace News Archive

The current medical device landscape and how it is evolving

Stericycle customers in pharmaceutical returns program to be serviced by Pharma Logistics

Seneca Biopharma, Inc., (Nasdaq: CUR), a clinical-stage biopharmaceutical company developing novel treatments for diseases of unmet medical need, will begin trading on the Nasdaq Capital Market under the ticker symbol, NASDAQ: SNCA beginning on November 1, 2019.

Development of novel therapies will drive market growth in North America

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented preclinical data at the 2019 North American Cystic Fibrosis Conference (NACFC) on ARO-ENaC, an inhaled RNAi therapeutic being developed as a potential treatment for cystic fibrosis (CF), which is a rare disease caused by genetic mutations that lead to mucus buildup in the lungs and pancreas.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the concurrent publication in The New England Journal of Medicine (NEJM) and The Lancet of results from two Phase 3 studies of TRIKAFTA™ (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF) in people ages 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, the most common CF-causing mutation.

The inheritance, not only of DNA, but of changes to proteins that package it, maintains the identity of cells as they multiply, a new study finds.

Blue Biotechnology Trends That Will Disrupt the Market: Derivation of Active Ingredients from Aquatic Organisms

Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”), a novel bioelectric medicine company bringing to market its proprietary CellFX™ System, announced today that the Company will report third quarter 2019 operational updates and highlights, along with financial results for third quarter on Thursday, November 7, 2019.

Pharmascience is proud to launch pms-FINGOLIMOD. A generic drug with demonstrated bioequivalence to the brand product GILENYA® for the treatment of relapsing multiple sclerosis (MS) in adults